KPTI
Karyopharm Therapeutics Stock Analysis
AI Rating
- Quality0/10
- Growth↓ 2/10
- Value↓ 0/10
KPTI Growth
- Revenue Y/Y↓ 0.57%
- EPS Y/Y↓ -90.54%
- FCF Y/Y↑ 40.95%
KPTI Profitability
- Gross margin ↑ 95.90%
- EPS margin↓ -134.20%
- ROIC 5Y↓ -35.27%
KPTI Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 2.3
- Interest coverage↓ -3.3
Karyopharm Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.